Crossover comparative study of latanoprost/timolol fixed combination with combined therapy comprised of latanoprost and timolol

Crossover comparative study of latanoprost/timolol fixed combination with combined therapy comprised of latanoprost and timolol - Xalacom crossover study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005426

Enrollment

Registered

2011-04-22

Start date

2011-04-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

glaucoma, ocular hypertension

Interventions

combined therapy: latanoprost and timolol 0.5% for 8 weeks latanoprost/timolol fixed combination (Xalacom) for 8 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Open-angle glaucoma or ocular hypertension IOP between 12 and 20 mmHg with latanoprost and timolol 0.5%; Concomitant use of other anti-glaucoma drugs permitted

Exclusion criteria

Exclusion criteria: Contraindication for latanoprost or timolol MD worse than or equal to -25dB (HFA 30-2) BCVA less than 0.5 Refractive error greater than or equal to +9.0D, or less than -9.0D Goldmann applanation tomometry or disc evaluation difficult or impossible History of intraocular surgery or laser Other ocular diseases which may affect the results

Design outcomes

Primary

Measure	Time frame
IOP after 8-week treatment	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026